- Home
- ALVO vs HAE Comparison
ALVO vs HAE Comparison
Compare ALVO & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- HAE
- Stock Information
- Founded
- ALVO 2013
- HAE 1971
- Country
- ALVO Luxembourg
- HAE United States
- Employees
- ALVO N/A
- HAE N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- HAE Medical/Dental Instruments
- Sector
- ALVO Health Care
- HAE Health Care
- Exchange
- ALVO Nasdaq
- HAE Nasdaq
- Market Cap
- ALVO 2.5B
- HAE 2.5B
- IPO Year
- ALVO N/A
- HAE 1991
- Fundamental
- Price
- ALVO $7.84
- HAE $49.99
- Analyst Decision
- ALVO Strong Buy
- HAE Buy
- Analyst Count
- ALVO 2
- HAE 8
- Target Price
- ALVO $14.00
- HAE $76.88
- AVG Volume (30 Days)
- ALVO 352.1K
- HAE 642.5K
- Earning Date
- ALVO 11-12-2025
- HAE 11-06-2025
- Dividend Yield
- ALVO N/A
- HAE N/A
- EPS Growth
- ALVO N/A
- HAE 46.89
- EPS
- ALVO 0.22
- HAE 3.28
- Revenue
- ALVO $562,478,000.00
- HAE $1,346,046,000.00
- Revenue This Year
- ALVO $34.94
- HAE N/A
- Revenue Next Year
- ALVO $39.55
- HAE $6.35
- P/E Ratio
- ALVO $36.05
- HAE $15.26
- Revenue Growth
- ALVO 82.19
- HAE 0.91
- 52 Week Low
- ALVO $7.35
- HAE $47.32
- 52 Week High
- ALVO $13.70
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- ALVO 40.91
- HAE 45.44
- Support Level
- ALVO $7.77
- HAE $48.98
- Resistance Level
- ALVO $8.50
- HAE $52.09
- Average True Range (ATR)
- ALVO 0.29
- HAE 1.25
- MACD
- ALVO -0.08
- HAE 0.21
- Stochastic Oscillator
- ALVO 5.49
- HAE 40.68
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.